As in our study, a dysregulated Wnt pathway and, more specifically, overexpression of FZD10 and FZD7 (another member of the Wnt cell-surface receptor family) were related to worse prognosis, so this FZD10 blocking antibody may have clinical potential by inhibiting the autocrine Wnt signalling pathway in ovarian cancer. Here, FZD7 is linked to ovarian cancer.